Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention (Q90104189)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

title

Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Mitchell Ho

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

author name string

Daniel J Urban

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Matthew D Hall

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Thomas Longerich

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Tim F Greten

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Ira Pastan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

publication date

14 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

11 April 2020

cites work

1 reference

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

7 January 2021

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

7 January 2021

Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis.

1 reference

7 January 2021

Glypican-3 Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma

1 reference

7 January 2021

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein

1 reference

7 January 2021

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

1 reference

7 January 2021

Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma

1 reference

7 January 2021

Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis

1 reference

7 January 2021

Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway

1 reference

7 January 2021

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

1 reference

7 January 2021

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

1 reference

7 January 2021

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

7 January 2021

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

1 reference

7 January 2021

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results.

1 reference

7 January 2021

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo

1 reference

7 January 2021

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

1 reference

7 January 2021

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

1 reference

7 January 2021

Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.

1 reference

7 January 2021

Fusion of an albumin-binding domain extends the half-life of immunotoxins.

1 reference

7 January 2021

High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening

1 reference

7 January 2021

Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).

1 reference

7 January 2021

The serum albumin-binding domain of streptococcal protein G is a three-helical bundle: a heteronuclear NMR study

1 reference

7 January 2021

Liver enzyme alteration: a guide for clinicians.

1 reference

7 January 2021

Novel Transgenic Mouse Model for Studying Human Serum Albumin as a Biomarker of Carcinogenic Exposure

1 reference

7 January 2021

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

1 reference

7 January 2021

Humanization of rabbit monoclonal antibodies via grafting combined Kabat/IMGT/Paratome complementarity-determining regions: Rationale and examples.

1 reference

7 January 2021

Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma

1 reference

7 January 2021

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1 reference

7 January 2021

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

1 reference

7 January 2021

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

1 reference

7 January 2021

Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas

1 reference

7 January 2021

Glypican-3 as a serum marker for hepatocellular carcinoma

1 reference

7 January 2021

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

1 reference

7 January 2021

Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice

1 reference

7 January 2021

A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

1 reference

7 January 2021

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

1 reference

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

7 January 2021

T cell exclusion, immune privilege, and the tumor microenvironment

1 reference

7 January 2021

Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.

1 reference

12 December 2020

Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling

1 reference

12 December 2020

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

1 reference

12 December 2020

A frizzled‐like cysteine rich domain in glypican‐3 mediates Wnt binding and regulates hepatocellular carcinoma tumor growth in mice

1 reference

12 December 2020

Identifiers

DOI

10.1002/HEP.30949

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31520528%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

0 references

1 reference